1. Introduction {#sec1-molecules-22-01023}
===============

*Capsella bursa-pastoris* (L.) Medik (Cruciferae), commonly known as 'shepherd's purse' is an annual plant which is widely distributed throughout the world \[[@B1-molecules-22-01023]\]. The roots of this plant have been used in Korean traditional medicine for the treatment of edema and hypertension \[[@B2-molecules-22-01023]\]. Previous phytochemical investigations of this plant led to reports of several flavonoids, terpenoids, and phenolic compounds with antimicrobial, antibacterial, antitumor, and liver catalase activities \[[@B3-molecules-22-01023],[@B4-molecules-22-01023],[@B5-molecules-22-01023],[@B6-molecules-22-01023],[@B7-molecules-22-01023],[@B8-molecules-22-01023]\]. Some of these compounds of *C. bursa-pastoris*, such as flavonoids and sulforaphane, have been reported to exhibit good antibacterial and anti-inflammatory activity \[[@B4-molecules-22-01023],[@B9-molecules-22-01023]\]. In the course of our continuing search for bioactive constituents in Korean medicinal plants, we found that the *n*-BuOH fraction of the MeOH extract of *C. bursa-pastoris* inhibited NO production in a lipopolysaccharide (LPS)-activated microglia BV-2 cell line. The *n*-BuOH fraction was subjected to repeated column chromatography with Diaion HP-20, silica gel, and semipreparative HPLC separation to yield a new sesquilignan glycoside **1**, and seven known compounds **2**--**8** ([Figure 1](#molecules-22-01023-f001){ref-type="fig"}). The structure of the new compound **1** was determined by spectroscopic methods, including 1D and 2D NMR (^1^H- and ^13^C-NMR, ^1^H-^1^H COSY, HSQC, HMBC, and NOESY), and HR-FABMS analysis. The known compounds **2**--**8** were identified by comparison of their spectroscopic data and specific optical rotation with reported data. The isolated compounds **1**--**8** were tested for their inhibitory effects on NO production in an LPS-activated microglia BV-2 cell line.

2. Results and Discussion {#sec2-molecules-22-01023}
=========================

2.1. Structure Elucidation {#sec2dot1-molecules-22-01023}
--------------------------

Purification of the *n*-BuOH layer by column chromatography afforded a new sesquilignan glycoside **1**, together with three known lignin glycosides **2**--**4** and four known phenolic glycosides **5**--**8**. The known compounds were identified as 7*S*, 8*R*, 8′*R*-(−)-lariciresinol-4,4′-bis-*O*-glucopyranoside (**2**) \[[@B10-molecules-22-01023]\], lariciresinol4′-*O*-β-[d]{.smallcaps}-glucoside (**3**) \[[@B11-molecules-22-01023]\], (+)-pinoresinol-β-[d]{.smallcaps}-glucoside (**4**) \[[@B12-molecules-22-01023]\], salidroside (**5**) \[[@B13-molecules-22-01023]\], 3-(4-β-[d]{.smallcaps}-glucopyranosyloxy-3,5-dimethoxy)-phenyl-2*E*-propanol (**6**) \[[@B14-molecules-22-01023]\], β-hydroxy-propiovanillone 3*-O*-β-[d]{.smallcaps}-glucopyranoside (**7**) \[[@B15-molecules-22-01023]\], and coniferin (**8**) \[[@B16-molecules-22-01023]\] by comparing their ^1^H-,^13^C-NMR and MS spectral data with values in the literature.

Compound **1** was obtained as a brownish gum. The molecular formula was established as C~36~H~44~O~14~ using HR-FABMS, which showed a positive ion \[M + Na\]^+^ at *m*/*z*: 723.2626 (calcd. for C~36~H~44~O~14~Na, 723.2629, so the molecular formula was deduced to be C~36~H~44~O~14~. The ^1^H-NMR spectrum of **1** revealed the presence of two 1,3,4-trisubstituted aromatic rings (δ~H~ 7.16 (d, *J* = 8.3 Hz, H-5′′), 7.15 (d, *J* = 8.2 Hz, H-5), 7.05 (d, *J* = 1.7 Hz, H-2), 7.01 (d, *J* = 1.7 Hz, H-2′′), 6.95 (dd, *J* = 8.2, 1.7 Hz, H-6), and 6.90 (dd, *J* = 8.2, 1.7 Hz, H-6″)), a 1,3,4,5-tetrasubstitued aromatic ring (δ~H~ 6.76 (s, H-6′), 6.78 (s, H-2′)), two oxygenated methines (δ~H~ 5.58 (d, *J* = 5.9 Hz, H-7) and 4.85 (m, H-7′′)), two oxygenated methylenes (δ~H~ 3.85 (m, H-9b), 3.78 (m, H-9a), and 3.88 (m, H-9′′a), 3.68 (dd, *J* = 10.9, 6.7 Hz, H-9b′′)), a methylene 2.96 ((dd, *J* = 13.5, 5.0 Hz, H-7′a), and 2.57 (dd, *J* = 13.3, 11.0 Hz, H-7′b)), three methines (δ~H~ 3.48 (m, H-8), 2.75 (sep, *J* = 6.5, 5.5 Hz, H-8′), and 2.38 (quin, *J* = 6.9 Hz, H-8″)), three methoxy groups (δ~H~ 3.88 (s, 3-OCH~3~), 3.87 (s, 5′-OCH~3~) and 3.84 (s, 3′′-OCH~3~)), and a glucopyanosyl unit (δ~H~ 4.91 (d, *J* = 7.3 Hz, H-1′′′), 3.69 (m, H-6′′′), 3.51 (m, H-2′′′), 3.41 (overlap, H-4′′′, 5′′′) and 3.39 (m, H-3′′′). The ^13^C-NMR spectrum displayed 36 carbon signals, including 18 aromatic carbons δ~C~ 151.1 (C-3″), 147.9 (C-4′, 3′), 147.8 (C-3), 147.5 (C-4, 4″), 145.5 (C-5′), 139.7 (C-1″), 135.7 (C-1), 134.9 (C-1′), 119.7 (C-6″), 119.5 (C-6), 118.4 (C-6′), 118.2 (C-5″), 118.1 (C-5), 114.7 (C-2′), 111.5 (C-2″) and 111.3 (C-2), three oxygenated carbons δ~C~ 88.6 (C-7), 83.9 (C-7″), and 73.5 (C-9′), three methylene carbons δ~C~ 65.1 (C-9), 60.5 (C-9″), 33.9 (C-7′) and three methine carbons δ~C~ 55.7 (C-8), 54.2 (C-8″), 44.0 (C-8′), and, three methoxy carbons (δ~C~ 56.9 and 56.8 (×2)), and glucose carbons δ~c~ 103.1 (C-1′′′), 78.5 (C-3′′′), 78.4 (C-5′′′), 75.1 (C-2′′′), 71.6 (C-4′′′), and 62.6 (C-6′′′) ([Table 1](#molecules-22-01023-t001){ref-type="table"}).

The ^1^H- and ^13^C-NMR spectra ([Table 1](#molecules-22-01023-t001){ref-type="table"}) were very similar to those of abiesol A \[[@B17-molecules-22-01023]\], except for the presence of a glucose unit in **1**. The positions of three methoxy groups were confirmed as 3-OCH~3~ (δ~H~ 3.88)/C-3 (δ~C~ 147.8), 5′-OCH~3~ (δ~C~ 3.87)/C-5′ (δ~C~ 145.5), and 3″-OCH~3~ (δ~H~ 3.84)/C-3″ (δ~C~ 151.1). HMBC correlation (H-1′′′ to C-4″) indicated that a D-glucose moiety was linked to C-4″ ([Figure 2](#molecules-22-01023-f002){ref-type="fig"}a), and identified the β form by the coupling constant (*J* = 7.3 Hz) \[[@B18-molecules-22-01023]\]. The stereochemistry of **1** was assigned on the basis of examination of the CD spectrum in combination with the NOESY experiment. The absolute configurations of C-7 and C-8 were confirmed as 7*R* and 8*S* from the positive Cotton effect at 223 nm and the negative effect at 245 and 291 nm in the CD spectrum \[[@B19-molecules-22-01023]\]. The absolute configurations of C-8′/C-7″/C-8″ were identified as 8′*S*, 7″*S* and 8*R* from the negative Cotton effect at 231 nm and 280 nm, respectively ([Figure S8, Supplementary Materials](#app1-molecules-22-01023){ref-type="app"}) \[[@B19-molecules-22-01023]\]. HMBC correlations and NOESY cross-peaks ([Figure 2](#molecules-22-01023-f002){ref-type="fig"}) reconfirmed the suggested structure of **1**. The enzymatic hydrolysis of **1** afforded [d]{.smallcaps}-glucose, which was identified by the sign of the specific rotation $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +48.2 (*c* = 0.03, H~2~O) and by co-TLC (CHCl~3~:MeOH:H~2~O = 2:1:0.1; *R*~f~ = 0.21) \[[@B20-molecules-22-01023]\] and the aglycone **1a**, which was identified by ^1^H-NMR and MS data \[[@B17-molecules-22-01023]\]. Thus, the structure of **1** was determined as (7*R*, 8*S*, 8′*S*, 7″*S*, 8″*R*)-abiesol A 4″-*O*-β-[d]{.smallcaps}-glucopyranoside, and it was named capselloside.

2.2. Anti-Inflammatory Activity {#sec2dot2-molecules-22-01023}
-------------------------------

Nitric oxide (NO) is one of the pro-inflammatory mediators and also a signaling molecule responsible for the induction of inflammation and pain through the pronounced induction of pro-inflammatory cytokines \[[@B21-molecules-22-01023]\]. It is believed to be produced excessively in the inflammatory conditions so it has been considered as a major biomarker for the screening of the anti-inflammatory activity of compound \[[@B22-molecules-22-01023]\]. Compounds that can inhibit the NO production possess an anti-inflammatory activity against LPS-induced neuroinflammation \[[@B23-molecules-22-01023]\].

The anti-inflammatory activities of the isolates **1**--**8** were evaluated by measuring the levels of nitric oxide (NO) produced in lipopolysaccharide (LPS)-activated microglia BV-2 cells \[[@B24-molecules-22-01023]\]. Compound **4** significantly inhibited LPS-stimulated NO production, with an IC~50~ value of 17.80 μM and compound **7** showed moderate NO production, with an IC~50~ value of 27.91 μM without cell toxicity ([Table 2](#molecules-22-01023-t002){ref-type="table"}), which represented more potent activity than the positive control, L-NMMA (20.76 μM).

3. Materials and Methods {#sec3-molecules-22-01023}
========================

3.1. General Experimental Procedures {#sec3dot1-molecules-22-01023}
------------------------------------

Optical rotations were measured on a P-1020 polarimeter in MeOH (Jasco, Easton, MD, USA). Infrared (IR) spectra were recorded on a IFS-66/S FT-IR spectrometer (Bruker, Karlsruhe, Germany). Circular dichroism (CD) spectra were measured on a Jasco J-715 spectropolarimeter using methanol as a solvent. Ultraviolet (UV) spectra were recorded using a UV-1601 UV-Visible spectrophotometer (Shimadzu, Tokyo, Japan). HR-FABMS spectra were obtained on a JMS700 mass spectrometer (JEOL, Peabody, MA, USA). TLC was performed using precoated silica gel F254 plates and RP-18 F254s plates (Merck, Darmstadt, Germany). NMR spectra, including COSY, HMQC, and HMBC experiments were recorded on an AVANCE III 700 NMR spectrometer at 700 MHz (^1^H) and 175 MHz (^13^C). (Bruker, Billerica, MA, USA). Preparative high performance liquid chromatography (HPLC) was conducted using a 306 pump (Gilson, Middleton, WI, USA) equipped with a Shodex refractive index detector (Shodex, New York, NY, USA) and a Phenomenex-Luna-10u-silica-(2) column (250 mm × 10.00 mm i.d.) or a YMC J'sphere ODS-M80 column (250 mm × 10.00 mm i.d.). Low-pressure liquid chromatography (LPLC) was carried out over a Li-Chroprep Lobar-A RP-18 column (240 mm × 10 mm i.d.; Merck) with an FMI QSY-0 pump (Teledyne Isco, Lincoln, NE, USA). Silica gel 60 and RP-C~18~ silica gel (230--400 mesh, Merck) were used for column chromatography. The packing material for macroporous adsorbent column chromatography was a Diaion HP-20 column (Sigma, St. Louis, MO, USA). Spots were detected by thin layer chromatography (TLC) under UV light or by heating after spraying with anisaldehyde-sulfuric acid.

3.2. Plant Materials {#sec3dot2-molecules-22-01023}
--------------------

Whole plants of *C. bursa-pastoris* (3 kg) were purchased from Anmyeon-Island, Chungcheongnam-do, Korea in March 2015. A voucher specimen (SKKU-NPL 1410) has been deposited in the herbarium of the School of Pharmacy, Sungkyunkwan University, Suwon, Korea.

3.3. Extraction and Isolation {#sec3dot3-molecules-22-01023}
-----------------------------

Whole plants of *C. bursa-pastoris* (3 kg) were extracted three times at room temperature with 80% aqueous MeOH (10 L × 1 day) and then filtered. The filtrate was evaporated under vacuum to afford a crude MeOH extract (280 g), which was suspended in distilled H~2~O and successively partitioned with *n*-hexane, CHCl*~3~*, EtOAc, and *n*-BuOH, yielding 33, 5, 4, and 26 g respectively. The BuOH-soluble layer (26 g) was separated on a Diaion HP-20 column eluted with a gradient solvent system of 100% H~2~O and 100% MeOH, yielding subfractions A (100% H~2~O) and B (100% MeOH). Subfraction B (7 g) was separated over a silica gel column (230--400 mesh, 300 g) with CHCl~3~--MeOH--H~2~O (5:1:0.1) to afford six subfractions (B1--B6). Subfraction B2 (168 mg) was chromatographed over a Lobar-A RP-18 column (25% MeCN) to give four subfractions (B21--B24). Subfraction B22 (54 mg) was purified by semi-preparative reversed-phase HPLC using a solvent system of 32% MeOH (flow rate; 2 mL/min) to isolate compound **4** (7 mg). Subfraction B24 (41 mg) was purified by semi-preparative reversed-phase HPLC using a solvent system of 45% MeOH (flow rate; 2 mL/min) to isolate compound **3** (6 mg). Subfraction B3 (1 g) was separated over a RP-C~18~ column (230--400 mesh, 150 g) with a solvent system of 10% MeOH to obtain eleven subfractions (B301--B311). Compounds **5** (7 mg), **8** (30 mg), **6** (9 mg), **7** (5 mg) and, **9** (13 mg) were acquired by purification of fractions B303 (17 mg), B304 (66 mg), B305 (21 mg), B306 (14 mg), and B311 (16 mg), respectively, using semi-preparative normal-phase HPLC with CHCl~3~--MeOH--H~2~O (5:1:0.1; flow rate; 2 mL/min). Subfraction B5 (1 g) was separated over a RP-C~18~ column (230--400 mesh, 150 g) with a solvent system of 10% MeOH to obtain ten subfractions (B501--B510). Compounds **1** (3 mg), and **2** (14 mg) were acquired by purification of fractions B503 (17 mg) and B505 (21 mg), respectively, using semi-preparative normal-phase HPLC with a solvent system of CHCl~3~--MeOH--H~2~O (2:1:0.1; flow rate; 2 mL/min).

3.4. Characterization {#sec3dot4-molecules-22-01023}
---------------------

Capselloside (**1**)*:* Brownish gum; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −34.0 (*c* = 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 280 (1.4), 228 (3.3), 214 (3.1) nm; IR (KBr) ν~max~ 3261, 2946, 2816, 1638, 1489, 1261 cm^−1^; CD (MeOH) λ~max~ (Δ ε) 291 (−), 280 (−) 257 (−) 230 (−) 223 (+); ^1^H (700 MHz) and ^13^C (175 MHz) NMR data, see [Table 1](#molecules-22-01023-t001){ref-type="table"}; HR-FABMS (positive-ion mode) *m*/*z*: 723.2626 \[M + Na\]^+^ (calcd. for C~36~H~44~O~14~Na, 723.2629).

3.5. Enzymatic Hydrolysis {#sec3dot5-molecules-22-01023}
-------------------------

Compound **1** (1.0 mg) in H~2~O (3.0 mL) was hydrolyzed with crude β-glucosidase (10.0 mg, from almonds; Sigma-Aldrich) at 37 °C for 48 h. The reaction mixture was extracted with CHCl~3~ (3 × 3 mL). The CHCl~3~ layer (0.6 mg) was chromatographed over a silica gel Waters Sep-Pak Vac 12 cc eluted with CHCl~3~--MeOH (30:1) to give the aglycone **1a** (0.4 mg), which was identified by ^1^H‑NMR and MS data. The sugar ([d]{.smallcaps}-glucose) from the aqueous phase of the hydrolysate of **1** was identified by silica gel TLC (CHCl~3~--MeOH--H~2~O 2:1:0.1; *R*~f~ = 0.21) comparison with a [d]{.smallcaps}-glucose standard. The specific rotation of the sugar obtained from **1** was $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +48.2 (*c* = 0.03, H~2~O).

3.6. Measurement of Nitric Oxide Production and Cell Viability in LPS-Activated BV-2 Cells {#sec3dot6-molecules-22-01023}
------------------------------------------------------------------------------------------

The inhibitory effect of the test compounds on LPS-stimulated NO production was studied using BV-2 cells. BV-2 cells were seeded on a 96-well plate (4 × 104 cells/well) and treated with or without different concentrations of the compounds. The cells were stimulated with LPS (100 µg/mL) and incubated for 24 h. The concentration of nitrite (NO~2~), a soluble oxidation product of NO, in the culture medium was measured using Griess reagent (0.1% *N*-1-naphthylethylenediamine dihydrochloride and 1% sulfanilamide in 5% phosphoric acid). Fifty microliters of supernatant was mixed with an equal volume of Griess reagent. Absorbance was measured after 10min using a microplate reader (Emax, Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 570 nm. L-NMMA, a well-known nitric oxide synthase (NOS) inhibitor, was used as a positive control. Graded sodium nitrite solution was used as a standard to calculate nitrite concentration. Cell viability was evaluated by observing the ability of viable cells to reduce the yellow-colored MTT to purple formazan, using an MTT assay.

4. Conclusions {#sec4-molecules-22-01023}
==============

We have isolated and identified from *C. bursa-pastoris* a new sesquilignan glycoside **1**, which we have named capselloside, together with seven known compounds **2**--**8** and evaluated their anti-inflammatory effects. Nitric oxide synthesis inhibition potency of phenolic glycosides suggests their anti-inflammatory activity against LPS-induced neuroinflammatory model in vitro. (+)-Pinoresinol-β-[d]{.smallcaps}-glucoside (**4**) showed the most potent anti-inflammatory effects and β-hydroxypropiovanillone 3-*O*-β-[d]{.smallcaps}-glucopyranoside (**7**) showed moderate NO production in an LPS-activated microglia BV-2 cell line. Compound **4** showed better potency than that of the commercial NOS inhibitor to inhibit LPS-induced NO production and neuroinflammation. In conclusion, our results collectively support the notion that phenolic glycosides from *Capsella bursa-pastoris* (L.) Medik may be potentially responsible for the observed in vitro anti-inflammatory activity in a LPS-induced neuroinflammatory model.
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![Chemical structures of compounds **1**--**8**.](molecules-22-01023-g001){#molecules-22-01023-f001}

![Key ^1^H-^1^H COSY, HMBC (**a**) and NOESY (**b**) correlations of **1**.](molecules-22-01023-g002){#molecules-22-01023-f002}

molecules-22-01023-t001_Table 1

###### 

^1^H (700 MHz) and ^13^C (175 MHz) NMR data of **1** in methanol-*d*~4~ (δ in ppm) ^a^.

  Position      δ~C~, Type    δ~H~ (*J* in Hz)
  ------------- ------------- -----------------------
  1             135.7, C      
  2             111.3, CH     7.05, d (1.7)
  3             147.8, C      
  4             147.5, C      
  5             118.1, CH     7.15, d (8.2)
  6             119.5, CH     6.95, dd (8.2, 1.7)
  7             88.6, CH      5.58, d (5.91)
  8             55.7, CH      3.48, m
  9             65.1, CH~2~   
  a                           3.78, m
  b                           3.85, m
  1′            134.9, C      
  2′            114.7, CH     6.78, s
  3′            147.9, C      
  4′            147.9, C      
  5′            145.5, C      
  6′            118.4, CH     6.76, s
  7′            33.9, CH~2~   
  a                           2.96, dd (13.5, 5.0)
  b                           2.57, dd (13.3, 11.0)
  8′            44.0, CH      2.75, sep (6.5, 5.5)
  9′            73.5, CH~2~   
  a                           3.78, m
  b                           4.05, dd (8.3, 6.6)
  1″            139.7, C      
  2″            111.5, CH     7.01, d (1.7)
  3″            151.1, C      
  4″            147.5, C      
  5″            118.2, CH     7.16, d (8.3)
  6″            119.7, CH     6.90, dd (8.2, 1.7)
  7″            83.9, CH      4.85, overlap
  8″            54.2, CH      2.38, quin (6.9)
  9″            60.5, CH~2~   
  a                           3.88, m
  b                           3.68, dd (10.9, 6.7)
  Glc-1′′′      103.1, CH     4.91, d (7.3)
  2′′′          75.1, CH      3.51, m
  3′′′          78.5, CH      3.39, m
  4′′′          71.6, CH      3.41, m
  5′′′          78.4, CH      3.41, m
  6′′′          62.6, CH      3.69, overlap
  OCH~3~ (3″)   56.9          3.84, s
  OCH~3~ (3)    56.8          3.88, s
  OCH~3~ (5′)   56.8          3.87, s

^a^ The assignments were based on HSQC and HMBC experiments.

molecules-22-01023-t002_Table 2

###### 

Effects of compounds **1**--**8** on NO production in LPS-activated BV-2 cells.

  Compound     IC~50~ ^a^ (µM)   Cell Viability ^b^ (%)
  ------------ ----------------- ------------------------
  **1**        75.13             103.04 ± 7.08
  **2**        48.80             116.68 ± 3.69
  **3**        30.70             109.17 ± 8.61
  **4**        17.80             117.36 ± 10.23
  **5**        31.14             116.09 ± 10.67
  **6**        62.21             110.02 ± 9.52
  **7**        27.91             119.20 ± 6.23
  **8**        49.21             111.55 ± 10.40
  ^c^ L-NMMA   20.76             112.89 ± 4.90

^a^ The IC~50~ value of each compound was defined as the concentration (µM) that caused 50% inhibition of NO production in LPS-activated BV-2 cells; ^b^ Cell viability after treatment with 20 µM of each compound was determined by the MTT assay and is expressed as a percentage (%). The results are averages of three independent experiments, and the data are expressed as mean ± SD; ^c^ L-NMMA was used as a positive control.
